We next assessed the in vivo antitumor killing efficacy of BsAbs targeting CD47 and CD38 in a mouse xenograft model using CB17-SCID mice implanted with the NCI-H929 multiple myeloma cell line. Here, CD38 is linked to plasma cell myeloma.